Viemed Healthcare (VMD)


Market Price (11/18/2026): $9.08 | Market Cap: $344.1 MilSector: Health Care | Industry: Life Sciences Tools & Services

Viemed Healthcare (VMD)


Market Price (11/18/2026): $9.08
Market Cap: $344.1 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%

Attractive yield
FCF Yield is 8.7%

Low stock price volatility
Vol 12M is 41%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more.

Weak multi-year price returns
2Y Excs Rtn is -27%, 3Y Excs Rtn is -41%

Key risks
VMD key risks include [1] its significant dependence on Medicare reimbursement for its core ventilator services and [2] challenges executing its growth-by-acquisition strategy.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 25%
1 Attractive yield
FCF Yield is 8.7%
2 Low stock price volatility
Vol 12M is 41%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Telehealth Platforms, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -27%, 3Y Excs Rtn is -41%
5 Key risks
VMD key risks include [1] its significant dependence on Medicare reimbursement for its core ventilator services and [2] challenges executing its growth-by-acquisition strategy.

VMD in ETFs

Weight = VMD's share of each fund

VTI0.00%
IWM0.01%
IWO0.02%
VTWO0.01%
IWV0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 5: down 10.9% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock fell as it reported Q3 earnings of $0.11 per share, missing estimates. This occurred as the broader market also declined significantly amid concerns about AI.

Up 18.0% from its Aug 20 low to Nov 4, down 10.3% since (S&P 500 up 0.8%)
The stock experienced a run mostly without specific company news. The largest daily gains occurred on August 21, October 28, and November 4 as the market also gained.

Show more
Prices as of 11/17/2026

Nov 5: down 10.9% the day after its Nov 4 earnings report (S&P 500 down 4.4%)
The stock fell as it reported Q3 earnings of $0.11 per share, missing estimates. This occurred as the broader market also declined significantly amid concerns about AI.

Up 18.0% from its Aug 20 low to Nov 4, down 10.3% since (S&P 500 up 0.8%)
The stock experienced a run mostly without specific company news. The largest daily gains occurred on August 21, October 28, and November 4 as the market also gained.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -22.3% change in VMD stock from 7/31/2026 to 11/17/2026 was primarily driven by a -26.6% change in the company's P/E Multiple.
(LTM values as of)731202611172026Change
Stock Price ($)11.679.07-22.3%
Change Contribution By: 
Total Revenues ($ Mil)2873108.3%
Net Income Margin (%)5.2%5.0%-3.1%
P/E Multiple30.122.1-26.6%
Shares Outstanding (Mil)38380.9%
Cumulative Contribution-22.3%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
VMD-22.3% 
Market (SPY)-1.7%23.2%
Sector (XLV)14.4%34.4%

Fundamental Drivers

The -8.9% change in VMD stock from 4/30/2026 to 11/17/2026 was primarily driven by a -12.7% change in the company's P/E Multiple.
(LTM values as of)430202611172026Change
Stock Price ($)9.969.07-8.9%
Change Contribution By: 
Total Revenues ($ Mil)27031014.8%
Net Income Margin (%)5.5%5.0%-8.9%
P/E Multiple25.322.1-12.7%
Shares Outstanding (Mil)3838-0.2%
Cumulative Contribution-8.9%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
VMD-8.9% 
Market (SPY)2.4%8.4%
Sector (XLV)27.9%28.7%

Fundamental Drivers

The 40.4% change in VMD stock from 10/31/2025 to 11/17/2026 was primarily driven by a 28.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)6.469.0740.4%
Change Contribution By: 
Total Revenues ($ Mil)24131028.8%
Net Income Margin (%)5.8%5.0%-13.2%
P/E Multiple18.322.121.1%
Shares Outstanding (Mil)40383.7%
Cumulative Contribution40.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
VMD40.4% 
Market (SPY)8.5%16.7%
Sector (XLV)30.6%30.8%

Fundamental Drivers

The 43.7% change in VMD stock from 10/31/2023 to 11/17/2026 was primarily driven by a 98.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)6.319.0743.7%
Change Contribution By: 
Total Revenues ($ Mil)15631098.8%
Net Income Margin (%)4.7%5.0%7.1%
P/E Multiple32.922.1-32.9%
Shares Outstanding (Mil)38380.6%
Cumulative Contribution43.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
VMD43.7% 
Market (SPY)81.6%24.0%
Sector (XLV)56.4%25.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
VMD Return-33%45%4%2%-7%22%17%
Peers Return3%-10%-27%-23%28%-14%-42%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
VMD Win Rate42%58%58%58%42%73% 
Peers Win Rate53%58%50%40%54%44% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
VMD Max Drawdown-54%-35%-49%-37%-30%-30% 
Peers Max Drawdown-33%-33%-62%-53%-42%-46% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, COCH, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventVMDS&P 500
2025 US Tariff Shock
  % Loss-22.0%-18.8%
  % Gain to Breakeven28.2%23.1%
  Time to Breakeven271 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-32.4%-9.5%
  % Gain to Breakeven47.8%10.5%
  Time to Breakeven105 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-34.2%-24.5%
  % Gain to Breakeven52.0%32.4%
  Time to Breakeven37 days427 days
2020 COVID-19 Crash
  % Loss-52.5%-33.7%
  % Gain to Breakeven110.7%50.9%
  Time to Breakeven28 days140 days

Compare to A, ATEC, CERS, COCH, FRNM

In The Past

Viemed Healthcare's stock fell -22.0% during the 2025 US Tariff Shock. Such a loss loss requires a 28.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventVMDS&P 500
2025 US Tariff Shock
  % Loss-22.0%-18.8%
  % Gain to Breakeven28.2%23.1%
  Time to Breakeven271 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-32.4%-9.5%
  % Gain to Breakeven47.8%10.5%
  Time to Breakeven105 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-34.2%-24.5%
  % Gain to Breakeven52.0%32.4%
  Time to Breakeven37 days427 days
2020 COVID-19 Crash
  % Loss-52.5%-33.7%
  % Gain to Breakeven110.7%50.9%
  Time to Breakeven28 days140 days

Compare to A, ATEC, CERS, COCH, FRNM

In The Past

Viemed Healthcare's stock fell -22.0% during the 2025 US Tariff Shock. Such a loss loss requires a 28.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Viemed Healthcare (VMD)

Viemed Healthcare, Inc. (VMD) is a healthcare company focused on providing in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients across the United States. The company's primary mission is to manage chronic respiratory conditions, enabling individuals to receive necessary treatments and equipment directly in their homes, promoting comfort and convenience outside of traditional hospital environments.

The core of Viemed's business involves comprehensive respiratory disease management, with a strong emphasis on conditions such as Chronic Obstructive Pulmonary Disease (COPD) and sleep apnea. Their main offerings include the leasing and sale of critical equipment like non-invasive and invasive ventilators, positive airway pressure (PAP) machines, percussion vests, and oxygen concentrator units. Additionally, the company provides various therapeutic solutions, including neuromuscular care services, oxygen therapy, and specialized in-home sleep apnea testing services, along with associated medical supplies.

Viemed primarily serves patients in the United States who are managing chronic respiratory illnesses. This includes individuals diagnosed with COPD, sleep apnea, or other conditions requiring ventilatory support, neuromuscular care, or ongoing oxygen therapy. By delivering essential medical services and equipment directly to patients' residences, Viemed caters to those seeking accessible, effective, and long-term management solutions for their respiratory health needs.

AI Analysis | Feedback

  • Imagine ResMed or Philips, but focused on the 'last mile': Viemed delivers, installs, and provides ongoing clinical support for advanced respiratory equipment directly to patients' homes.
  • Think of it as DaVita for chronic respiratory patients: instead of kidney care, Viemed provides comprehensive in-home medical equipment and clinical services for conditions like COPD and sleep apnea.

AI Analysis | Feedback

  • In-Home Durable Medical Equipment (DME): Provides and leases a variety of medical devices, including invasive and non-invasive ventilators, PAP machines, percussion vests, and oxygen concentrators.
  • Post-Acute Respiratory Healthcare Services: Offers comprehensive management solutions for respiratory diseases, such as COPD, utilizing various therapies and equipment.
  • Sleep Apnea Management Solutions: Delivers services, including in-home testing, and provides equipment like PAP machines for the diagnosis and treatment of sleep apnea.
  • Neuromuscular Care and Oxygen Therapy Services: Provides specialized care and associated equipment for patients requiring neuromuscular support and oxygen therapy.

AI Analysis | Feedback

Major Customers of Viemed Healthcare (VMD)

Viemed Healthcare (VMD) primarily sells its durable medical equipment and post-acute respiratory healthcare services directly to individual patients in their homes. Based on the company description, its major customer categories include:

  • Patients with Chronic Obstructive Pulmonary Disease (COPD): Individuals suffering from COPD who require non-invasive ventilation, percussion vests, and other respiratory therapies and related equipment.
  • Patients requiring Sleep Apnea Management: Individuals diagnosed with sleep apnea who need Positive Airway Pressure (PAP) machines, automatic continuous positive airway pressure (APAP), bi-level positive airway pressure (BiPAP) machines, and in-home sleep apnea testing services.
  • Patients needing Neuromuscular Care and Oxygen Therapy: Individuals with various neuromuscular conditions or other respiratory issues requiring invasive or non-invasive ventilation, oxygen concentrator units, and other specialized respiratory equipment and services.

AI Analysis | Feedback

null

AI Analysis | Feedback

Casey Hoyt, Chief Executive Officer

Casey Hoyt was appointed Chief Executive Officer of Viemed Healthcare in December 2017. He is committed to the company's patient-centric focus and "live your life" mission. A long-time advocate for helping patients through clinical excellence, education, and technology, Hoyt co-founded Viemed subsidiaries, Sleep Management, LLC, and Home Sleep Delivered, LLC in 2006, prior to Viemed Healthcare's evolution in 2012. He has also led numerous other successful businesses throughout his career, including a global trade show display and event marketing services company.

Trae Fitzgerald, Chief Financial Officer

Trae Fitzgerald serves as the Chief Financial Officer and Principal Accounting Officer of Viemed Healthcare, a position he has held since November 2017. As CFO, his total compensation in 2024 was reported as $872,178.

Todd Zehnder, Chief Operating Officer

Todd Zehnder has been Viemed's Chief Operating Officer since 2017. Throughout his tenure with the company, he has also held roles as Vice President of Finance and Chief Strategy Officer. A Certified Public Accountant, Zehnder began his career at KPMG. He also held multiple senior executive positions, including Chief Operating Officer and Chief Financial Officer, for 15 years at PetroQuest Energy Inc., an NYSE-listed company.

Michael Moore, President

Michael Moore is the President of Viemed Healthcare. He was involved in the founding of Viemed Healthcare in 2006.

Michael Freeman, Chief Business Development Officer

Michael Freeman joined Viemed Healthcare as Chief Business Development Officer in August 2022. Before his role at Viemed, Freeman served for nearly 20 years as Senior Vice President of Corporate Development at LHC Group, Inc. In this capacity, he was responsible for new partnership and acquisition activities, including identifying targets, managing due diligence, planning integration, and negotiating agreements. He was involved in over 150 acquisition and partnership transactions at LHC. Collectively, with Jeremy Trahan, he was integrally involved in over 100 transactions at LHC Group valued at approximately $1.9 billion.

AI Analysis | Feedback

The key risks to Viemed Healthcare (VMD) are primarily centered around the highly regulated healthcare environment, the reliance on third-party medical equipment, and the inherent challenges of in-home medical device usage.

  1. Government Regulation and Reimbursement Policies: Viemed Healthcare operates within a complex and extensively regulated U.S. healthcare system. The company faces ongoing exposure to U.S. healthcare reform, anti-kickback statutes, and other compliance risks. A significant portion of Viemed's revenue comes from Medicare and Medicaid, accounting for 40% and 43% respectively in 2025 and 2024. Any reduction or elimination of coverage or reimbursement for their products by these government programs could lead to similar reductions by commercial third-party payors, thereby adversely affecting the business and its financial results. Durable medical equipment (DME) companies like Viemed are subject to strict federal oversight by organizations such as the U.S. Department of Health and Human Services' Office of Inspector General (HHS-OIG) and the Centers for Medicare and Medicaid Services (CMS), with common violations involving complex billing and marketing practices.
  2. Product Recalls and Supply Chain Dependence: Viemed distributes and sells specific medical devices, such as Royal Philips BiPAP and CPAP devices and ventilators. A voluntary recall of such products due to potential health risks, as occurred with Philips devices, can have an adverse impact on Viemed's business, reputation, financial performance, and future prospects. Furthermore, there is a risk that vendors may not always be able to provide the necessary equipment to satisfy demand in an emerging market, which could affect Viemed's ability to serve patients.
  3. Usability Challenges and Risks of Home Medical Devices: A significant hazard for Viemed's business model, which focuses on in-home care, stems from the usability challenges and inherent risks associated with medical devices used in residential settings. Medical devices like ventilators, often designed for professional use in clinical environments, can be complex for patients and non-professional caregivers to operate safely and effectively at home. ECRI, a non-profit organization focused on healthcare safety, identified the use of medical devices in the home as the top health technology safety hazard for 2024, citing risks from insufficient training for users, potential misuse or malfunction, and the possibility of undetected or unreported errors.

AI Analysis | Feedback

The emergence of direct-to-consumer (DTC) models for durable medical equipment, particularly for sleep apnea devices such as PAP machines, poses a clear threat. These models, often facilitated by online telehealth consultations and manufacturer partnerships, allow patients to obtain equipment directly, bypassing traditional DME providers like Viemed Healthcare. This shift in the distribution and service delivery model can lead to reduced reliance on intermediaries, impacting Viemed's market share and revenue stream in its sleep apnea management segment.

AI Analysis | Feedback

Viemed Healthcare, Inc. (VMD) operates within several significant addressable markets related to in-home durable medical equipment (DME) and post-acute respiratory healthcare services in the United States.

Addressable Markets for Viemed Healthcare's Main Products and Services:

  • U.S. Respiratory Durable Medical Equipment (DME) Market: This market, which directly encompasses many of Viemed's offerings such as oxygen therapy, non-invasive home ventilators, and connected PAP machines, was valued at approximately USD 4.01 billion in 2025. It is projected to grow to about USD 5.89 billion by 2033, with a compound annual growth rate (CAGR) of 4.93% from 2026 to 2033. Respiratory and sleep devices constitute approximately 35% of the total U.S. DME market revenue.
  • U.S. Durable Medical Equipment (DME) Market (Overall): The broader U.S. durable medical equipment market was valued at an estimated USD 43.58 billion in 2024 and is predicted to reach around USD 79.57 billion by 2034, expanding at a CAGR of 6.21% from 2025 to 2034. This market is projected to exceed USD 110 billion by 2028.
  • Sleep Apnea Devices Market (North America/Global): Viemed Healthcare provides sleep apnea management solutions and in-home sleep apnea testing. The global sleep apnea devices market was estimated at USD 4.5 billion in 2023 and is projected to reach USD 6.9 billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. North America held the largest share of this market, accounting for 48.1% in 2023. Another report indicated the global market for sleep apnea devices was USD 5.40 billion in 2024 and is expected to grow to USD 10.2 billion by 2033, with a CAGR of 7.32% from 2026 to 2033. North America also consistently dominated the sleep apnea devices market in 2023 and 2024.
  • COPD Addressable Market (Viemed's Niche): Viemed Healthcare specifically addresses a niche within the COPD market. It is estimated that approximately 1.25 million treatable patients in the U.S. suffer from Stage 4 COPD with chronic respiratory failure, representing an estimated USD 20 billion in potential revenue for providers like Viemed.

AI Analysis | Feedback

Viemed Healthcare, Inc. (VMD) is expected to drive future revenue growth over the next two to three years through several key initiatives and market trends:

  1. Expansion of Sleep Therapy Services: Viemed Healthcare is experiencing significant growth in its sleep therapy segment, particularly with PAP (Positive Airway Pressure) therapy patients and resupply services. The company reported a 62% year-over-year increase in PAP therapy patient count and a 49% rise in sleep resupply patients in 2025. This area is considered a crucial and accelerating growth driver, supported by a large underdiagnosed obstructive sleep apnea market and increasing clinical awareness.
  2. Growth in Maternal Health: The acquisition of Lehan's Medical Equipment in 2025 marked Viemed Healthcare's expansion into maternal health. This segment contributed approximately $9 million to the company's revenue in 2025 and is projected to become a more significant contributor as the company expands these services beyond the initial markets of the acquisition throughout 2026. This expansion also helps diversify the company's payer mix.
  3. Diversification of Home Medical Equipment (HME) Offerings: While traditionally strong in ventilation, Viemed Healthcare is actively diversifying its HME rental portfolio. The company has seen growth in other non-ventilator HME rentals, including oxygen and airway clearance therapies, alongside its sleep therapy devices. This strategic diversification aims to reduce reliance on any single product category and broaden the company's service offerings.
  4. Organic Growth through Market Expansion and Densification: Viemed Healthcare's strategy includes organic growth through both geographic expansion into new target markets and densifying its presence in existing markets. This approach focuses on increasing its patient base and strengthening its operational footprint across the United States.
  5. Strategic Acquisitions: The company maintains an active pipeline for mergers and acquisitions (M&A) to acquire complementary services and platforms that can leverage its existing national infrastructure, including payer relationships and clinical operations. The successful integration and positive contribution of the Lehan's acquisition serve as a testament to this inorganic growth strategy.

AI Analysis | Feedback

Share Repurchases

  • Viemed Healthcare authorized a new share repurchase program through March 2027, allowing for the purchase of up to 1,930,131 common shares, representing approximately 5% of its total outstanding shares as of March 4, 2026.
  • Across three prior share repurchase programs, Viemed returned approximately $26.3 million to shareholders by repurchasing about 4.5 million shares.
  • A share repurchase program authorized in June 2025, for up to 1,976,441 shares, was fully completed by September 23, 2025, at a total cost of approximately $13.2 million.

Outbound Investments

  • Viemed Healthcare completed the acquisition of Lehan's Medical Equipment in 2025, which contributed to an increase in net revenues for the year.
  • The company views selective acquisitions as an opportunistic component of its broader capital allocation framework, alongside investment in organic growth.

Capital Expenditures

  • Net capital expenditures for the year ended December 31, 2025, totaled approximately $23.8 million.
  • Net capital expenditures for the year ended December 31, 2024, totaled approximately $27.5 million.
  • Viemed's capital allocation framework supports continued investment in organic growth and selective acquisitions.

Better Bets vs. Viemed Healthcare (VMD)

Peer Outperformance in Life Sciences Tools & Services

VMD has outperformed 93% of its 109 Life Sciences Tools & Services peers over 5Y. Among the peers that beat it is AXGN. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that VMD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
81%
of 125 industry peers · 44.2% return
3Y
68%
of 115 industry peers · 18.3% return
5Y
93%
of 109 industry peers · 63.1% return
Life Sciences Tools & Services peers with revenue growth within 4pp of VMD's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
VMD Viemed Healthcare 22.3% 22.1x 44.2%18.3%63.1% —
AXGN Axogen 20.6% -95.7x 134.9%841.7%399.7% +337pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is VMD's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services ← 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

VMDAATECCERSCOCHFRNMMedian
NameViemed H.Agilent .Alphatec Cerus Envoy Me.Freenome  
Mkt Price9.08172.247.131.926.879.868.11
Mkt Cap0.348.61.10.4-1.01.0
Rev LTM3107,3728402270-310
Op Inc LTM261,639-26-2-24--2
FCF LTM301,267-100-22-0
FCF 3Y Avg101,257-71-3-22--3
CFO LTM781,609613-22-61
CFO 3Y Avg601,6305-1-21-5

Growth & Margins

VMDAATECCERSCOCHFRNMMedian
NameViemed H.Agilent .Alphatec Cerus Envoy Me.Freenome  
Rev Chg LTM21.8%8.6%15.3%13.7%11.1%-13.7%
Rev Chg 3Y Avg22.3%2.0%23.2%13.8%0.4%-13.8%
Rev Chg Q12.2%8.1%12.6%9.5%57.1%-12.2%
QoQ Delta Rev Chg LTM2.9%1.9%3.0%2.3%11.6%-2.9%
Op Inc Chg LTM48.0%13.5%65.3%74.0%-19.5%-48.0%
Op Inc Chg 3Y Avg26.3%5.3%38.1%54.0%-20.1%-26.3%
Op Mgn LTM8.3%22.2%-3.0%-1.1%-10,343.3%--1.1%
Op Mgn 3Y Avg7.6%22.1%-12.4%-4.2%-9,221.1%--4.2%
QoQ Delta Op Mgn LTM0.2%0.7%1.7%-0.4%1,067.8%-0.7%
CFO/Rev LTM25.1%21.8%7.3%1.5%-9,624.2%-7.3%
CFO/Rev 3Y Avg22.5%23.8%-0.6%-0.5%-8,907.8%--0.5%
FCF/Rev LTM9.7%17.2%-1.2%0.2%-9,710.4%-0.2%
FCF/Rev 3Y Avg3.4%18.3%-12.1%-1.9%-9,121.7%--1.9%

Valuation

VMDAATECCERSCOCHFRNMMedian
NameViemed H.Agilent .Alphatec Cerus Envoy Me.Freenome  
Mkt Cap0.348.61.10.4-1.01.0
P/S1.16.61.31.7--1.5
P/Op Inc13.429.6-43.9-156.8---15.2
P/EBIT14.027.5-26.4-1,640.6---6.2
P/E22.133.7-12.9-52.9--4.6
P/CFO4.430.218.3110.7--24.2
Total Yield4.5%3.6%-8.0%-1.9%--0.8%
Dividend Yield0.0%0.6%0.0%0.0%-0.0%0.0%
FCF Yield 3Y Avg2.9%3.0%-8.5%-1.0%--0.9%
D/E0.00.10.50.2-0.20.2
Net D/E-0.00.00.50.0--0.20.0

Returns

VMDAATECCERSCOCHFRNMMedian
NameViemed H.Agilent .Alphatec Cerus Envoy Me.Freenome  
1M Rtn-4.2%-0.4%-31.8%-11.9%2.8%-16.1%-8.1%
3M Rtn-0.4%16.2%-25.2%-30.4%-7.0%-26.7%-16.1%
6M Rtn-5.5%56.3%-13.3%-28.9%-7.2%-24.2%-10.2%
12M Rtn44.4%20.1%-64.1%25.5%5.4%-24.2%12.7%
3Y Rtn18.4%55.7%-35.2%9.7%-24.5%-24.2%-7.2%
1M Excs Rtn-1.7%4.9%-27.8%-9.9%8.6%-18.0%-5.8%
3M Excs Rtn5.4%14.8%-23.0%-28.8%-3.4%-23.9%-13.2%
6M Excs Rtn-6.4%55.5%-14.1%-29.8%-8.0%-25.1%-11.1%
12M Excs Rtn32.0%8.1%-74.3%8.3%-7.3%-34.4%0.4%
3Y Excs Rtn-40.9%-5.6%-99.9%-48.7%-94.9%-92.5%-70.6%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment270224183139 
COVID-19 response sales and services    9
Equipment and supply sales    9
Other home medical equipment rentals    14
Service revenues    2
Ventilator rentals, non-invasive and invasive    84
Total270224183139117


Price Behavior

Price Behavior
Market Price$9.07 
Market Cap ($ Bil)0.3 
First Trading Date03/16/2018 
Distance from 52W High-26.4% 
   50 Days200 Days
DMA Price$9.29$9.67
DMA Trendindeterminateup
Distance from DMA-2.3%-6.2%
 3M1YR
Volatility36.1%40.8%
Downside Capture75.5418.85
Upside Capture103.1558.24
Correlation (S&P 500)53.6%15.3%
VMD Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.890.59-0.45-0.420.220.56
Up Beta-1.81-1.43-4.74-2.29-0.490.46
Down Beta1.211.160.740.650.540.60
Up Capture155%108%-18%-23%48%31%
Bmk +ve Days12182862130427
Stock +ve Days14263570142379
Down Capture44%27%92%-32%13%82%
Bmk -ve Days10253664121325
Stock -ve Days8172953103349

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with VMD
VMD42.1%40.8%0.96-
Sector ETF (XLV)24.2%16.9%1.1031.2%
Equity (SPY)10.2%13.8%0.4515.8%
Gold (GLD)-6.3%28.8%-0.23-1.7%
Commodities (DBC)31.6%21.3%1.18-16.4%
Real Estate (VNQ)10.0%14.2%0.4221.3%
Bitcoin (BTCUSD)-31.4%43.7%-0.75-2.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with VMD
VMD9.0%41.5%0.32-
Sector ETF (XLV)8.6%15.4%0.3622.2%
Equity (SPY)10.9%17.3%0.4624.4%
Gold (GLD)15.5%19.2%0.654.3%
Commodities (DBC)7.1%19.6%0.25-2.6%
Real Estate (VNQ)0.9%19.0%-0.0622.2%
Bitcoin (BTCUSD)-0.6%51.4%0.1712.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with VMD
VMD5.3%48.1%0.32-
Sector ETF (XLV)12.4%16.8%0.6125.0%
Equity (SPY)14.9%18.0%0.7028.0%
Gold (GLD)11.2%16.6%0.554.4%
Commodities (DBC)7.4%18.2%0.325.8%
Real Estate (VNQ)5.8%20.7%0.2422.7%
Bitcoin (BTCUSD)57.2%66.3%0.9712.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity1.5 Mil
Short Interest: % Change Since 10152026-1.7%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest8.5 days
Basic Shares Quantity38.1 Mil
Short % of Basic Shares4.0%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-10.9%-9.7% 
8/3/2026-15.9%-20.3%-24.7%
5/5/2026-12.2%-3.5%1.4%
3/4/2026-7.5%0.0%6.1%
11/5/2025-2.6%1.9%6.4%
8/6/20257.9%13.6%6.7%
5/7/2025-11.7%-5.5%-7.6%
3/10/20255.4%0.1%-10.0%
...
SUMMARY STATS   
# Positive101612
# Negative15912
Median Positive7.3%2.6%7.0%
Median Negative-6.8%-7.6%-9.1%
Max Positive18.2%30.4%40.5%
Max Negative-15.9%-22.1%-26.3%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/2026-10.9%-9.7% 
8/3/2026-15.9%-20.3%-24.7%
5/5/2026-12.2%-3.5%1.4%
3/4/2026-7.5%0.0%6.1%
11/5/2025-2.6%1.9%6.4%
8/6/20257.9%13.6%6.7%
5/7/2025-11.7%-5.5%-7.6%
3/10/20255.4%0.1%-10.0%
11/6/2024-1.5%0.1%-5.7%
8/7/202410.0%8.6%12.3%
5/6/2024-6.8%-14.2%-8.2%
3/6/20246.5%1.1%-9.4%
11/1/202312.0%14.3%26.2%
8/9/2023-3.7%-3.8%-11.3%
5/8/2023-2.7%0.0%-8.8%
3/2/2023-12.2%2.2%7.3%
11/1/2022-1.5%3.9%10.6%
8/2/2022-14.2%-22.1%-25.5%
5/3/202210.2%9.2%11.3%
3/7/202218.2%30.4%40.5%
11/2/20213.2%7.8%-7.4%
8/2/2021-1.9%1.0%-7.1%
5/3/2021-2.8%-7.6%-26.3%
3/3/20216.7%3.1%3.6%
11/5/20204.1%-4.7%3.2%
SUMMARY STATS   
# Positive101612
# Negative15912
Median Positive7.3%2.6%7.0%
Median Negative-6.8%-7.6%-9.1%
Max Positive18.2%30.4%40.5%
Max Negative-15.9%-22.1%-26.3%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/03/202610-Q
03/31/202605/05/202610-Q
12/31/202503/04/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/10/202510-K
09/30/202411/06/202410-Q
06/30/202408/07/202410-Q
03/31/202405/06/202410-Q
12/31/202303/06/202410-K
09/30/202311/01/202310-Q
06/30/202308/09/202310-Q
03/31/202305/08/202310-Q
12/31/202203/02/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/03/202610-Q
03/31/202605/05/202610-Q
12/31/202503/04/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202403/10/202510-K
09/30/202411/06/202410-Q
06/30/202408/07/202410-Q
03/31/202405/06/202410-Q
12/31/202303/06/202410-K
09/30/202311/01/202310-Q
06/30/202308/09/202310-Q
03/31/202305/08/202310-Q
12/31/202203/02/202310-K
09/30/202211/01/202210-Q
06/30/202208/02/202210-Q
03/31/202205/03/202210-Q
12/31/202103/07/202210-K
09/30/202111/02/202110-Q
06/30/202108/03/202110-Q
03/31/202105/03/202110-Q
12/31/202003/03/202110-K
09/30/202011/04/202010-Q
06/30/202008/04/202010-Q
03/31/202005/05/202010-Q
12/31/201903/04/202010-K

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Net RevenueReported316.00 Mil318.00 Mil320.00 Mil0.3% RaisedGuidance: 317.00 Mil for 2026
2026 Adjusted EBITDAReported64.00 Mil65.00 Mil66.00 Mil-1.5% LoweredGuidance: 66.00 Mil for 2026
2026 Net Capital Expenditures (% of net revenue)Reported8.0%8.5%9.0% -0.8%LoweredGuidance: 9.25% for 2026


Prior: Q2 2026 Earnings Reported 8/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Net RevenueReported314.00 Mil317.00 Mil320.00 Mil0.3% RaisedGuidance: 316.00 Mil for 2026
2026 Adjusted EBITDAReported64.00 Mil66.00 Mil68.00 Mil-1.5% LoweredGuidance: 67.00 Mil for 2026
2026 Net Capital ExpendituresReported0.090.090.1 -0.5%LoweredGuidance: 0.1 for 2026

Q1 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported312.00 Mil316.00 Mil320.00 Mil  RaisedGuidance: 315.00 Mil for 2026
2026 Adjusted EBITDAReported65.00 Mil67.00 Mil69.00 Mil0 AffirmedGuidance: 67.00 Mil for 2026
2026 Net Capital ExpendituresReported0.090.10.11 -1.0%LoweredGuidance: 0.11 for 2026

Q4 2025 Earnings Reported 3/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Net RevenueReported310.00 Mil315.00 Mil320.00 Mil15.8% Higher NewGuidance: 272.00 Mil for 2025
2026 Adjusted EBITDAReported65.00 Mil67.00 Mil69.00 Mil9.8% Higher NewGuidance: 61.00 Mil for 2025
2026 Net Capital ExpendituresReported0.10.110.12   

Insider Activity

Updated 8/19/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Frazier, WilliamChief Medical OfficerDirectSell626202611.7210,000117,200858,068Form
2Smokoff, Timothy DirectSell626202611.5020,000229,967868,333Form
3Moore, MichaelPresidentby Moore Faster LLCSell32020268.7765,000570,05013,907,571Form
4Moore, MichaelPresidentby Moore Faster LLCSell32020269.2140,232370,53715,203,979Form
5Moore, MichaelPresidentby Moore Faster LLCSell32020269.4231,570297,38915,929,634Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Frazier, WilliamChief Medical OfficerDirectSell626202611.7210,000117,200858,068Form
2Smokoff, Timothy DirectSell626202611.5020,000229,967868,333Form
3Moore, MichaelPresidentby Moore Faster LLCSell32020268.7765,000570,05013,907,571Form
4Moore, MichaelPresidentby Moore Faster LLCSell32020269.2140,232370,53715,203,979Form
5Moore, MichaelPresidentby Moore Faster LLCSell32020269.4231,570297,38915,929,634Form
6Cambre, JeromeVice President of SalesDirectSell81420257.324,88035,737616,551Form
7Moore, MichaelPresidentDirectSell81320257.3350,090367,160926,094Form
Core Cache Last Updated: 11/17/2026